Highest-materiality recent filing
Amylyx Q1 net loss $41.3M; Phase 3 avexitide topline data in Q3 2026
Net loss of $41.3M ($0.37 per share) vs $35.9M ($0.42) in Q1 2025; cash used in operations.
Completed enrollment in Phase 3 LUCIDITY trial.
Net loss for FY2025: $144.7M ($1.53/share) vs $301.7M ($4.43/share) in FY2024.
Amylyx selects GLP-1 antagonist AMX0318 as development candidate for post-bariatric hypoglycemia
AMX0318 is a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases.
Amylyx Q3 net loss narrows to $34.4M; cash $344M after $191M offering
Net loss $34.4M ($0.37/sh) vs $72.7M ($1.07/sh) in Q3 2024; R&D $19.9M, SG&A $16.2M.
Amylyx launches $164M common stock offering at $10.00 per share to fund avexitide launch
Offering of 17.5M shares (2.625M option) at $10.00/share; net proceeds ~$164M, up to ~$188.7M.
Amylyx discontinues AMX0035 program for PSP after Phase 2b miss
AMX0035 failed to show differences vs placebo on primary or secondary outcomes at Week 24.
Amylyx Q1 net loss $35.9M, cash $204.1M; avexitide Phase 3 underway
Q1 net loss $35.9M ($0.42/share), down from $118.8M ($1.75/share) YoY on lower R&D and SG&A costs.
Amylyx reports Q4 net loss of $37.5M, cash runway extended through 2026 after $65.5M raise
Net loss for Q4 2024 was $37.5M ($0.55 per share); FY2024 net loss of $301.7M ($4.43 per share).
Amylyx prices 17.1M-share public offering at $3.50/sh for ~$56.9M net proceeds
Offering of 17,142,857 common shares at $3.50 per share, with 30-day option for up to 2,571,428 additional shares.
Amylyx reports Q3 net loss of $72.7M; cash $234.4M; pipeline updates on AMX0035, avexitide, AMX0114
Net loss of $72.7M ($1.07 loss per share) vs net income of $20.9M in Q3 2023; acquired IPR&D expense of $36.2M for avexitide.
HELIOS Phase 2: AMX0035 improves C-peptide AUC by +3.8 min*ng/mL at Week 24 in Wolfram syndrome
Primary endpoint: C-peptide AUC improved at Week 24 (ITT +3.8 min*ng/mL; Per Protocol +20.2) and sustained through Week 48 (+36.7).
Amylyx Q2 net loss $72.7M; revenue negative after RELYVRIO withdrawal; avexitide acquisition
Q2 net loss $72.7M ($1.07/share) vs net income $22.1M ($0.31) a year ago; revenue negative $(1.0)M after RELYVRIO/ALBRIOZA withdrawal.
Amylyx completes acquisition of Avexitide from Eiger for $35.1M
Acquired Avexitide from Eiger BioPharmaceuticals for $35.1 million plus cure costs and assumed liabilities.
Amylyx acquires Avexitide from bankrupt Eiger BioPharma for $35.1M
Acquires substantially all assets for Avexitide, a GLP-1 receptor antagonist, from Eiger BioPharmaceuticals.
Amylyx Q1 net loss $118.8M; discontinues RELYVRIO/ALBRIOZA; inventory write-down $110.5M
Net loss of $118.8M ($1.75 diluted per share) vs. net income of $1.6M in Q1 2023.
Interim Phase 2 data for AMX0035 shows clinically meaningful effects in Wolfram syndrome (n=8)
C-peptide AUC increased +15.6 ng*min/mL at Week 24; 7 of 8 participants had shorter time to peak C-peptide.
Amylyx pulls RELYVRIO from market after Phase 3 miss, cuts 70% of staff
Voluntarily discontinues RELYVRIO/ALBRIOZA in U.S. and Canada; no new patients after today.
Amylyx Phase 3 ALS trial misses primary endpoint; may withdraw RELYVRIO
PHOENIX trial: no significant difference on ALSFRS-R at Week 48 (p=0.667); secondary endpoints also missed.
Amylyx reports FY 2023 net income $49.3M vs loss; product revenue $380.8M
Full-year 2023 net product revenue $380.8M; Q4 revenue $108.4M vs $102.7M in Q3 2023.
On March 14, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of Amylyx Pharmaceuticals, Inc. (the “Company”) appointed Bernhardt Zeiher, MD, FCCP, FACP to fill a vacancy on the Board as a Class I director
Max materiality 1.00 · Median 0.65 · Most common event other_material